Fair value (multi-method)
Four independent methods triangulate what ALNY is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$22,330.80
Method range
$16.80 – $22,330.80
median $803.76
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $22,330.80 | +8,263.91% |
| Exit multiple | $1,169.02 | +337.85% |
| Analyst target | $438.50 | +64.24% |
| Graham number | $16.80 | -93.71% |
- Forward DCF$22,330.80
- Exit multiple$1,169.02
- Analyst target$438.50
- Graham number$16.80
Stock price
$266.99
FCF / share (TTM)
$0.37
3Y FCF CAGR
220.8%
Fair value @ hist. growth
$722,063.39
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied FCF growth
44.6%
per year over your projection horizon
Margin of safety 100.0% vs hist-growth DCF
Historical 3Y CAGR
220.8%
Your model implies
44.6%
Analyst consensus is EPS-only — no comparable FCF / share estimate to show on this basis.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Undiscounted FCF per share over 10 years at 221% annual growth.
Cumulative FCF covers the current price by year 6.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | 43.3% | 41.2% | 38.8% | 35.8% | 32.1% |
| 5.0% | 43.4% | 41.3% | 38.9% | 35.9% | 32.2% |
| 6.0% | 48.0% | 46.4% | 44.6% | 42.5% | 40.1% |
| 7.0% | 52.1% | 50.8% | 49.3% | 47.7% | 45.8% |
| 8.0% | 55.8% | 54.6% | 53.4% | 52.0% | 50.6% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
PEG
5.37
Demanding vs growth
Net cash
$379M
Total debt − cash
Beta
0.27
Vs market benchmark
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.